Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review.
BACKGROUND The prognosis of metastatic nasopharyngeal carcinoma (mNPC) remains dismal despite recent advances of locoregional and systemic therapy. The incorporation of programmed death-1 (PD-1) inhibitors into first-line chemotherapy has transformed the therapeutic landscape; however, optimal treatment strategies beyo...